Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Romosozumab Administered as 1 or 2 SC Injections in Healthy Participants
NCT07811999Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of romosozumab in osteoporosis (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity, Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07811999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811999.